In terms of side effects and tolerability, the advantage goes to PE-22-28
2021 Oct 26;11(5):517-525." Accessed on April 3, 2024, at The BMJ - "Long term health consequences of obesity." Accessed on April 3, 2024, at American Pharmacists Association (APhA) - "Compounding FAQs." Accessed on April 3, 2024, at Centers for Disease Control and Prevention (CDC) - "How Overweight and Obesity Impacts Your Health." Accessed on June 18, 2024, at CDC - "Consequences of Obesity." Accessed on April 3, 2024, at Drugs.com - "Tirzepatide User Reviews for Diabetes, Type 2." Accessed on April 3, 2024, at National Academies Press (NAP) - "Drug Compounding: An Interactive Learning Experience." Accessed on April 3, 2024, at Accreditation Commission for Health Care (ACHC) - "Pharmacy Compounding Accreditation." Accessed on April 3, 2024, at Accreditation Council for Pharmacy Education (ACPE) - "ACPE - Continuing Pharmacy Education." Accessed on April 3, 2024, at PubMed Central (PMC) - "BMJ Open
Severity of Condition : The extent of gut damage or inflammation affects healing time
References Ludwig MQ, Coester B, Gordian D, et al
CSF, cerebrospinal fluid
